上海凯宝药业股份有限公司 2025 年半年度 非经营性资金占用及其他关联资金往来情况汇总表 编制单位：上海凯宝药业股份有限公司 单位：万元 汇总表第 1 页 | | | 占用方与 上市公司 | 上市公司核算 | 2025 年期 | 2025 年度占用累 | 2025 年度占用 | 2025 年度偿 | 2025 年期 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 的关联关 | 的会计科目 | 初占用资金 | 计发生金额（不 | 资金的利息(如 | 还累计发生 | 末占用资 | 占用形成原因 | 占用性质 | | | | 系 | | 余额 | 含利息） | 有) | 金额 | 金余额 | | | | 现控股股东、实际控制人及 | | | | | | | | | | | | 其附属企业 | | | | | | | | | | | | 小计 | - | - | - | - | - | - | - | - | - | - | | 前控股股东、实际控制人及 | | | | ...

上海凯宝药业股份有限公司 证券代码：300039 证券简称：上海凯宝 公告编号：2025-036 为使投资者全面了解公司的经营成果、财务状况及未来发展规划，公司《2025 年半年度报告》于 2025 年 8 月 28 日在中国证监会指定的创业板信息披露网站：巨 潮资讯网（http://www.cninfo.com.cn）上披露，敬请投资者注意查阅。 特此公告。 上海凯宝药业股份有限公司董事会 2025 年 8 月 27 日 2025 年半年度报告披露提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 上海凯宝药业股份有限公司（以下简称"公司"）第六届董事会第十次会议审 议通过了公司《2025 年半年度报告》。 ...

证券代码：300039 证券简称：上海凯宝 公告编号：2025-040 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 上海凯宝药业股份有限公司(以下简称"公司")第六届监事会第七次会议通知 于 2025 年 8 月 16 日以邮件方式送达全体监事。会议于 2025 年 8 月 27 日上午在公 司会议室以现场和通讯相结合的方式召开，会议应参会监事三名，实际参会监事三 名。本次会议的召集、召开符合《公司法》、《公司章程》、《公司监事会议事规 则》的有关规定。会议由监事会主席主持，经全体监事审议表决，通过了以下议案： 二、审议通过了《2025 年半年度募集资金存放与使用情况的专项报告》的议案 公司监事会经过认真审核，认为公司募集资金的管理、使用及运作程序符合《创 业板上市公司规范运作指引》等有关规则和公司《募集资金管理办法》的规定，募 集资金的实际使用合法、合规，不存在违反法律、法规及损害股东利益的行为。 上海凯宝药业股份有限公司 第六届监事会第七次会议决议公告 一、审议通过了《2025 年半年度报告》及《2025 年半年度报告摘要》 经全体监事认真核查认为：《 ...

证券代码：300039 证券简称：上海凯宝 公告编号：2025-039 上海凯宝药业股份有限公司 第六届董事会第十次会议决议公告 具体内容详见中国证监会指定的创业板信息披露网站上的相关公告。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 上海凯宝药业股份有限公司（以下简称"公司"）第六届董事会第十次会议通 知于 2025 年 8 月 16 日以邮件、书面的方式送达全体董事。会议于 2025 年 8 月 27 日上午在公司会议室以现场和通讯相结合的方式召开，会议应参会董事九名，实际 参会董事九名。本次会议召开符合《公司法》等相关法律法规和《公司章程》、《公 司董事会议事规则》的有关规定。会议由董事长主持，经全体董事审议和表决，通 过以下决议： 一、审议通过了《2025 年半年度报告》及《2025 年半年度报告摘要》 公司《2025 年半年度报告》及《2025 年半年度报告摘要》内容真实、准确、完 整地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：同意 9 票、反对 0 票、弃权 0 票。 特此公告。 上海凯宝药业股份有限公司董事 ...

Section I Important Notice, Table of Contents, and Definitions [Important Notice](index=2&type=section&id=Important%20Notice) The company's board, supervisory board, and senior management guarantee the report's accuracy, while the financial officers confirm the financial statements' integrity - The company's board, supervisory board, and senior management guarantee the semi-annual report's content is true, accurate, and complete, with no false records, misleading statements, or major omissions[3](index=3&type=chunk) - Company head Mu Jingwei, chief financial officer Chen Youlong, and head of accounting Li Yaru declare that the financial report is true, accurate, and complete[3](index=3&type=chunk) - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital[4](index=4&type=chunk) [Table of Contents](index=3&type=section&id=Table%20of%20Contents) This section lists the eight main chapters of the semi-annual report, covering important notices, company profile, management discussion, corporate governance, significant events, share changes, bond information, and financial reports - The report contains eight main chapters, from important notices to financial reports[6](index=6&type=chunk) [Reference Documents](index=4&type=section&id=Reference%20Documents) This section lists documents available for inspection, including the original semi-annual report, signed financial statements, and publicly disclosed company announcements - Reference documents include the original **2025** semi-annual report signed by the chairman, signed and sealed financial report texts, and original copies of all company documents and announcements publicly disclosed during the reporting period[8](index=8&type=chunk) - Reference documents are available at the company's Board of Directors Office[9](index=9&type=chunk) [Definitions](index=5&type=section&id=Definitions) This section defines common terms and abbreviations used in the report, covering regulatory bodies, exchanges, company entities, and the reporting period - Defines regulatory bodies such as the China Securities Regulatory Commission, Shenzhen Stock Exchange, and National Medical Products Administration[10](index=10&type=chunk) - Clarifies that "the Company" and "Shanghai Kaibao" refer to Shanghai Kaibao Pharmaceutical Co., Ltd[10](index=10&type=chunk) - The reporting period refers to January **1**, **2025**, to June **30**, **2025**[10](index=10&type=chunk) Section II Company Profile and Key Financial Indicators [1. Company Profile](index=6&type=section&id=1.%20Company%20Profile) The company, listed on the Shenzhen Stock Exchange under stock code 300039, is officially known as Shanghai Kaibao Pharmaceutical Co., Ltd - Stock Abbreviation: Shanghai Kaibao, Stock Code: **300039**[12](index=12&type=chunk) - Stock Exchange: Shenzhen Stock Exchange[12](index=12&type=chunk) - Legal Representative of the Company: Mu Jingwei[12](index=12&type=chunk) [2. Contact Persons and Information](index=6&type=section&id=2.%20Contact%20Persons%20and%20Information) This section provides contact details for the company's Board Secretary and Securities Affairs Representative for investor communication - Board Secretary: Ren Liwang, Contact Number: **021-37572069**, Email: kbyydmb@126.com[13](index=13&type=chunk) - Securities Affairs Representative: Ma Congying, Contact Number: **021-37572069**, Email: kbyydmb@126.com[13](index=13&type=chunk) [3. Other Information](index=6&type=section&id=3.%20Other%20Information) No changes occurred in the company's contact information, disclosure channels, or registration details during the reporting period - The company's registered address, office address and postal code, website, and email address remained unchanged during the reporting period[14](index=14&type=chunk) - The securities exchange website and media names and URLs for the company's semi-annual report disclosure, and the location for semi-annual report availability, remained unchanged during the reporting period[15](index=15&type=chunk) - The company's registration status remained unchanged during the reporting period[16](index=16&type=chunk) [4. Key Accounting Data and Financial Indicators](index=7&type=section&id=4.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) The company's operating revenue and net profit attributable to shareholders decreased, while operating cash flow, total assets, and net assets increased Major Accounting Data and Financial Indicators (Current Period vs. Prior Period) | Indicator | Current Period (yuan) | Prior Period (yuan) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 604,655,893.63 | 829,151,714.24 | -27.08% | | Net Profit Attributable to Parent Company Shareholders | 121,954,089.17 | 142,139,016.05 | -14.20% | | Net Profit Attributable to Parent Company Shareholders After Non-Recurring Gains and Losses | 117,382,833.75 | 142,818,008.61 | -17.81% | | Net Cash Flow from Operating Activities | 159,806,070.06 | 131,071,740.10 | 21.92% | | Basic EPS (yuan/share) | 0.1166 | 0.1359 | -14.20% | | Diluted EPS (yuan/share) | 0.1166 | 0.1359 | -14.20% | | Weighted Average ROE (%) | 6.31% | -10.92% | 17.23% | Major Accounting Data and Financial Indicators (Period-End vs. Prior Year-End) | Indicator | Period-End (yuan) | Prior Year-End (yuan) | Period-End vs. Prior Year-End Change (%) | | :--- | :--- | :--- | :--- | | Total Assets | 4,674,066,400.80 | 4,518,469,414.47 | 3.44% | | Net Assets Attributable to Parent Company Shareholders | 4,263,452,029.25 | 4,102,051,563.35 | 3.93% | [5. Differences in Accounting Data Under Domestic and Overseas Accounting Standards](index=7&type=section&id=5.%20Differences%20in%20Accounting%20Data%20Under%20Domestic%20and%20Overseas%20Accounting%20Standards) The company reported no differences in net profit and net assets between Chinese and international or overseas accounting standards - The company reported no differences in net profit and net assets between financial reports disclosed under International Accounting Standards and Chinese Accounting Standards during the reporting period[18](index=18&type=chunk) - The company reported no differences in net profit and net assets between financial reports disclosed under overseas accounting standards and Chinese Accounting Standards during the reporting period[19](index=19&type=chunk) [6. Non-Recurring Gains and Losses and Amounts](index=7&type=section&id=6.%20Non-Recurring%20Gains%20and%20Losses%20and%20Amounts) Non-recurring gains and losses totaled **4.57 million yuan**, primarily from asset disposal, government grants, and fair value changes of financial assets Non-Recurring Gains and Losses and Amounts | Item | Amount (yuan) | | :--- | :--- | | Gains/Losses from Disposal of Non-Current Assets (incl. write-back of impairment provisions) | 187,254.57 | | Government Grants Recognized in Current P&L (excluding those closely related to normal operations, policy-compliant, standard-based, and with continuous impact) | 2,569,578.24 | | Gains/Losses from Fair Value Changes and Disposal of Financial Assets/Liabilities Held by Non-Financial Enterprises (excluding effective hedging related to normal operations) | 2,941,585.75 | | Other Non-Operating Income and Expenses | -403,599.18 | | Less: Income Tax Impact | 723,524.75 | | Minority Interest Impact (after tax) | 39.21 | | **Total** | **4,571,255.42** | - The company has no other profit and loss items that meet the definition of non-recurring gains and losses, nor does it classify non-recurring gains and losses as recurring gains and losses[22](index=22&type=chunk) Section III Management Discussion and Analysis [1. Principal Business Activities During the Reporting Period](index=9&type=section&id=1.%20Principal%20Business%20Activities%20During%20the%20Reporting%20Period) The company primarily engages in modern Chinese medicine R&D, production, and sales, with a focus on respiratory, cardiovascular, and digestive product lines [(I) Overview of the Industry](index=9&type=section&id=(I)%20Overview%20of%20the%20Industry) The pharmaceutical manufacturing industry, particularly traditional Chinese medicine, continues to grow with supportive policies focusing on innovation and quality - Pharmaceutical manufacturing is a vital component of the national economy, with continuously rising market demand, and traditional Chinese medicine holds unique advantages and value[24](index=24&type=chunk) - In the first half of **2025**, pharmaceutical industry policies were intensively introduced around three main themes: "inheriting innovation, quality improvement, and industrial upgrading," promoting high-quality industry development[24](index=24&type=chunk) - Policies include the "Opinions on Comprehensively Deepening the Reform of Drug and Medical Device Regulation to Promote High-Quality Development of the Pharmaceutical Industry" and the "Opinions on Improving the Quality of Traditional Chinese Medicine to Promote High-Quality Development of the Traditional Chinese Medicine Industry"[24](index=24&type=chunk)[25](index=25&type=chunk) [(II) Company's Industry Position](index=9&type=section&id=(II)%20Company's%20Industry%20Position) As a Shanghai High-Tech Enterprise, the company holds a strong market position with its patented Tanreqing Injection, a national strategic reserve medicine - The company is a Shanghai High-Tech Enterprise, committed to the modernization of traditional Chinese medicine, and was approved for **2

Group 1 - Shanghai Kaibao (300039) responded to investor inquiries on August 22 regarding the products and operational status of Shanghai Yizhong, directing investors to refer to Shanghai Yizhong's periodic reports [1]

上海凯宝表示，痰热清胶囊获批新增新型冠状病毒感染的适应症，将进一步扩大产品适用范围， 提升 市场竞争力及品牌知名度。（全景网） 痰热清胶囊为上海凯宝主营产品痰热清系列产品之一，是公司独家品种，功能主治:清热，化痰，解 毒。用于风温肺热病属风热袭肺证，症见发热，恶风，咳嗽，咯痰，或咽痛，流涕，口干等。此次获得 国家药监局《药品注册证书》，新增适应症"在新型冠状病毒感染的常规治疗中，可用于轻型引起的发 热、咳嗽、咽痛等。" 7月1日，上海凯宝（300039）发布公告称，公司于近日收到国家药品监督管理局签发的痰热清胶囊《药 品注册证书》，药品名称为痰热清胶囊。 ...

Core Viewpoint - Shanghai Kaibao (300039.SZ) announced the completion of a share reduction plan by its controlling shareholder's action party, resulting in a decrease in shareholding percentage below 39% [1][2]. Share Reduction Details - The action party, Xinxiang Kaiyi Trading Co., Ltd., reduced its holdings by 9,921,000 shares from July 24 to July 30, 2025, accounting for 0.9485% of the total share capital, with an average selling price of 6.85 CNY per share, resulting in a cash inflow of approximately 67.96 million CNY [1][2]. - Following the reduction, the total shares held by the controlling shareholder and its action parties decreased from 415,455,841 shares to 405,534,841 shares, reducing their ownership percentage from 39.72% to 38.77% [2]. Financial Performance Overview - In 2024, the company reported a revenue of 1.473 billion CNY, a year-on-year decline of 7.57%, while the net profit attributable to shareholders increased by 14.55% to 376 million CNY [3][4]. - The net profit excluding non-recurring gains rose by 21.16% to 353 million CNY, and the net cash flow from operating activities was 279 million CNY [3][4]. - For Q1 2025, the company experienced a revenue drop of 15.74% to 401 million CNY, with a net profit of 84.29 million CNY, down 4.71% year-on-year [5].

Company Overview - Shanghai Kaibao's stock price is reported at 6.80 yuan, down 0.87% from the previous trading day, with a trading range of 6.77 to 6.93 yuan and a total transaction amount of 354 million yuan [1] - The company specializes in the research, production, and sales of traditional Chinese medicine, with key products including Tan Re Qing injection [1] Shareholder Activity - The controlling shareholder's concerted action partner, Xinxiang Kaiyi Trading Co., Ltd., reduced its stake in the company by 9.92 million shares between July 24 and July 30, accounting for 0.9485% of the total share capital [1] Financial Performance - In the first quarter of 2025, the company achieved an operating income of 401 million yuan and a net profit of 84.29 million yuan [1] Market Activity - On July 31, the main funds experienced a net outflow of 31.2036 million yuan [2]

本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 公司控股股东、实际控制人的一致行动人减持计划实施完成 暨权益变动触及 1%整数倍的公告 公司控股股东、实际控制人的一致行动人新乡市凯谊商贸有限公司保证向本公 司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 上海凯宝药业股份有限公司（以下简称"公司"或"本公司"）于 2025 年 7 月 1 日披露了《关于公司控股股东、实际控制人的一致行动人减持股份的预披露公 告》（公告编号：2025-031）。 近日，公司收到控股股东、实际控制人的一致行动人新乡市凯谊商贸有限公司 （以下简称"凯谊商贸"）出具的《关于股份减持计划实施完成的告知函》。凯谊 商贸于 2025 年 7 月 24 日至 2025 年 7 月 30 日，通过集中竞价交易方式合计减持公 司股份 9,921,000 股，占公司总股本的 0.9485%，减持情况与此前已披露的减持计 划一致且在计划范围内，截止本公告披露日，本次减持计划已实施完成。 上述减持完成后，公司控股股东、实际控制人穆竟伟及其一致行动人张艳琪、 穆竟男、凯谊商贸合计持有公司股份数由 415,455 ...